ES2176776T3 - Ligandos del neuropeptido-y. - Google Patents

Ligandos del neuropeptido-y.

Info

Publication number
ES2176776T3
ES2176776T3 ES97939524T ES97939524T ES2176776T3 ES 2176776 T3 ES2176776 T3 ES 2176776T3 ES 97939524 T ES97939524 T ES 97939524T ES 97939524 T ES97939524 T ES 97939524T ES 2176776 T3 ES2176776 T3 ES 2176776T3
Authority
ES
Spain
Prior art keywords
neuropeptide
ligands
neuropeptide ligands
formula
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97939524T
Other languages
English (en)
Inventor
Vlad Edward Gregor
Yufeng Hong
Anthony Lai Ling
Eileen Valenzuela Tompkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2176776T3 publication Critical patent/ES2176776T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical

Abstract

Compuesto de fórmula en donde A es O, S, o N-R, en donde R es un alquilo de cadena corta (C1-C8); D es O, S o N-R7; W es N, CH o C-R8; R1 y R3 son independientemente H, radicales alquilo de C1-C14, lineales o ramificados, cíclicos o acíclicos, saturados o insaturados, opcionalmente substituidos por grupos hidroxi, oxialquilo de cadena corta, tioalquilo, oxiarilo o tioarilo, en donde dichos grupos que soportan arilos son substituidos opcionalmente por grupos halógeno, oxialquilo de cadena corta, tioalquilo, alquilo de cadena corta, trifluorometoxi, trifluoroetoxi o trifluorometilo, y opcionalmente dichos grupos alquilo están substituidos por estructuras cíclicas seleccionadas del grupo que consta de anillos que tienen un tamaño de anillo de entre 3 y 10 átomos, o dichos grupos alquilo están substituidos por partes aromáticas o heteroaromáticas, conteniendo opcionalmente dichos grupos arilo o heteroarilo substituyentes en el anillo arílico seleccionado del grupo consistente en grupos alquilode cadena corta, oxialquilo, amino, aminoalquilo de cadena corta, aminoacilo de cadena corta, halógenos, y trifluo rometilo o trifluorometoxi; R2 es en donde W2 es C=O, SO2, C(O)NH; SO; o está ausente; Q es (a) un (-CH2-)z substituido o no substituido, en donde z=1 a 12, y cuando -CH2- está subs tituido, los grupos substituyentes son alquilo de cadena corta, arilo o heteroarilo; y cuando z>1, al menos un grupo -CH2- está reemplazado opcionalmente por un heteroátomo seleccionado del grupo consis tente en O, S o un N substituido o no substituido, en donde la parte substituyente se selecciona del grupo consistente en alquilo de cadena corta, arilo, heteroarilalquilo e hidrógeno; (b) un anillo carbocíclico o heterocíclico saturado de fórmula (-CH2-)x en donde l y m son de 0-5, y en donde x=3-12, preferiblemente de 3-8, y opcionalmente, uno o más grupos -CH2- se substituyen por un radical seleccionado del grupo consistente en alquilo de cadena corta saturado o insaturado, cicloalquilo, arilo y heteroarilo; y opcionalmente al menos uno de los grupos CH2- está reem plazado por un heteroátomo seleccionado del grupo consistente en O, S, Se y N substituido o no substituido, y cuando N está substituido, el grupo substituyente se selecciona del grupo consistente en alquilo de cadena corta, arilo, heteroarilo e hidrógeno; (c) un anillo aromático carbocíclico o heterocíclico de fórmula (-CH=CH-)y en donde l y m son de 0-5, y en donde y opcionalmente al menos uno de los grupos -CH- está substituido por X1, X2 o tanto X1 como X2 en donde X es cualquier substituyente cíclico, por ejemplo grupos alquilos saturados o insaturados, lineales o ramificados, grupos oxialquilos de cadena corta o halógenos, y opcionalmente, al menos uno de los grupos -CH- está reemplazado por N, o alternativamente, uno de los grupos -CH=CH- está reemplazado por un heteroátomo seleccionado del grupo consistente en O, S, Se y N-R11; también opcionalmente, al menos uno de los grupos -CH=CH- es una unión con la cual se puede fusionar otra estructura cíclica, bien saturada o bien insaturada, formando de esta manera sistemas aromáticos o heteroaromáticos condensados seleccionados, por ejemplo, del grupo consistente en clases de naftaleno, indole, benzofurano, quinolina, quinazolina y benzodioxano; X3 es un substituyente en Q el cual puede ser H, alquilo de cadena corta, arilo, oxialquilo de cadena corta, hidroxi, trifluorometilo, y substituyentes cíclicos similares y comunes. R4 se selecciona del grupo consistente en las siguientes fórmulas generales: en donde A1 es O, S, NH o N-alquilo de cadena corta o arilo; R5 a R9, R11 y R12 se seleccionan independientemente del grupo consistente en H, radicales alquilo de C1 a C14, lineales o ramificados, saturados o insaturados, cíclicos o acíclicos, substituidos o no substituidos, o radicales arilos o heteroarilos, y cuando cualquiera de los R5 a R9, R11 o R12 es un radical arilo o heteroarilo substituido, el grupo substituyente se selecciona de los miembros del grupoconsistente en halógeno, oxialquilo de cadena corta, tioalquilo, alquilo de cadena corta, trifluorometoxi y trifluorometilo, y cuando cualquiera de los R5 a R9, R11 o R12 es un radical alquilo substituido, la parte substituyente se selecciona del grupo consistente en sistemas cíclicos no aromáticos que tienen de 3 a 14 átomos de anillo, y sistemas aromáticos y heteroaromáticos y anillos heterocíclicos que tienen de 4- 12 miembros de anillo, y dichos anillos aromáticos y heteroaromáticos opcionalmente están substituidos por radicales seleccionados del grupo consistente en alquilo de cadena corta, oxialquilo, amino, aminoalquilo de cadena corta, amidoacilo de cadena corta, halógenos, perfluoroalquilo, y perfluoroalquilo de cadena corta; o R6 es H, alquilo de C1 a C14, lineal o ramificado, cíclico o acíclico, saturado o insaturado; arilo; heteroarilo; arilalquilo de cadena corta; heteroarilalquilo de cadena corta; arilalquilo de cadena corta condensado; heteroarilalquilo de cadena corta condensado; diarilalquilo de cadena corta; bisheteroarilalquilo de cadena corta; o heteroarilalquilarilo de cadena corta; o derivados parcial o totalmente saturados de los mismos; o R6 puede ser R6 el cual es R6-NH o R6-N-alquilo de cadena corta; R10 es hidrógeno, grupos alquilos de C1-C12, lineales o ramificados, saturados o insaturados, cíclicos o acíclicos, que contienen opcionalmente enlaces dobles o triples; un arilo, opcionalmente substituido con grupos tales como halógeno, alquilo de cadena corta, oxialquilo, aminoalquilo, dialquilaminoalquilo de cadena corta, hidroxi; arilalquilo; oxiarilalquilo; 2-tetrahidrofurfurilo; 3-tetrahidrofurfurilo; hidroxial quilo terminal con cadenas de hidrocarburo de C2-C10 y amidoalquilo tal como el 2-acetamidoetilo; o R9 y R10 pueden formar opcionalmente un anillo de 3 a 10 miembros; y los compuestos comprenden cualquier isómero ópticamente activo de los mismos en forma de isómeros ópticos separados, puros o parcialmente purificados o mezclas racémicas delos mismos; y las sales farmacéuticamente aceptables de los mismos.
ES97939524T 1996-08-23 1997-08-22 Ligandos del neuropeptido-y. Expired - Lifetime ES2176776T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2579196P 1996-08-23 1996-08-23

Publications (1)

Publication Number Publication Date
ES2176776T3 true ES2176776T3 (es) 2002-12-01

Family

ID=21828075

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97939524T Expired - Lifetime ES2176776T3 (es) 1996-08-23 1997-08-22 Ligandos del neuropeptido-y.

Country Status (11)

Country Link
US (1) US6849733B1 (es)
EP (1) EP0984778B1 (es)
JP (1) JP2001502296A (es)
AT (1) ATE218859T1 (es)
AU (1) AU4159297A (es)
CA (1) CA2268051A1 (es)
DE (1) DE69713402T2 (es)
DK (1) DK0984778T3 (es)
ES (1) ES2176776T3 (es)
PT (1) PT984778E (es)
WO (1) WO1998007420A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
SE9802207D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
SE9802206D0 (sv) * 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
EP1033366A3 (en) * 1999-02-18 2000-12-27 Pfizer Products Inc. Amide derivatives useful as Neuropeptide Y (NPY) antagonists
US6355807B1 (en) 1999-08-24 2002-03-12 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
US6774243B2 (en) 1999-08-24 2004-08-10 Agouron Pharmaceuticals, Inc. Efficient synthetic routes for the preparation of rhinovirus protease inhibitors and key intermediates
DZ3415A1 (fr) 2000-08-31 2002-03-07 Chiron Corp Guanidinobenzamides comme mc4-r agonistes.
CA2425285A1 (en) * 2000-10-30 2002-05-10 Warner-Lambert Company Llc Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis
EP1767525A1 (en) 2001-04-09 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Guanidino compounds as melanocortin-4 receptor (MC4-R) agonists
ATE478867T1 (de) 2002-05-23 2010-09-15 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
JP4806628B2 (ja) 2003-05-05 2011-11-02 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤
AU2004249120B2 (en) 2003-05-23 2008-07-24 Glaxosmithkline Guanidino-substituted quinazolinone compounds as MC4-R agonists
JP2007509898A (ja) 2003-11-03 2007-04-19 プロビオドルグ エージー 神経障害治療に有用な組合せ
MXPA06005736A (es) 2003-11-19 2006-12-14 Chiron Corp Compuestos de quinazolinona con bioacumulacion reducida.
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
WO2006108218A1 (en) * 2005-04-15 2006-10-19 Regenertech Pty Limited Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration
US7273882B2 (en) * 2005-06-21 2007-09-25 Bristol-Myers Squibb Company Aminoacetamide acyl guanidines as β-secretase inhibitors
HUE032640T2 (en) 2005-11-08 2017-10-30 Vertex Pharma Heterocyclic modulator of ATP-binding cassette transcripts
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7657504B2 (en) * 2006-10-10 2010-02-02 Microsoft Corporation User interface for displaying images of sights
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
JP5379692B2 (ja) 2006-11-09 2013-12-25 プロビオドルグ エージー 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8969386B2 (en) 2007-05-09 2015-03-03 Vertex Pharmaceuticals Incorporated Modulators of CFTR
CN101910156B (zh) 2007-12-07 2013-12-04 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式
PT2639222T (pt) 2007-12-07 2016-11-01 Vertex Pharma Processo de produção de ácidos cicloalquilcarboxamido-piridina-benzoicos
CN103382201B (zh) 2008-02-28 2016-12-28 沃泰克斯药物股份有限公司 作为cftr调节剂的杂芳基衍生物
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
CN102791704B (zh) 2010-03-10 2015-11-25 前体生物药物股份公司 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
SI3150198T1 (sl) 2010-04-07 2021-11-30 Vertex Pharmaceuticals Incorporated Farmacevtski sestavki 3-(6-(1-(2,2-difluorobenzo(D)(1,3)dioksol-5-il) ciklopropankarboksamido)-3-metilpiridin-2-il)benzojske kisline in dajanje le-teh
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US10231932B2 (en) 2013-11-12 2019-03-19 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
BR112017010406B1 (pt) 2014-11-18 2021-03-09 Vertex Pharmaceuticals Incorporated processo de realização de teste de alta produtividade de cromatografia líquida de alta eficiência
WO2018097126A1 (ja) * 2016-11-25 2018-05-31 日本曹達株式会社 グアニジン化合物および殺菌剤
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7535681A (en) * 1981-08-24 1983-03-08 Rorer International (Overseas) Inc. Treatment of infections
US4562209A (en) * 1981-08-24 1985-12-31 William H. Rorer, Inc. Promotion of feed efficiency in animals
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
DK0448765T3 (da) * 1990-03-30 1994-09-19 Heumann Pharma Gmbh & Co Anvendelse af guanidinderivater til fremstilling af et lægemiddel med NPY-antagonistisk virkning
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
US5583238A (en) 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
DE4301452A1 (de) * 1993-01-20 1994-07-21 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
FR2701480B1 (fr) 1993-02-15 1995-05-24 Sanofi Elf Composés à groupe sulfamoyle et amidino, leur procédé de préparation et les compositions pharmaceutiques les contenant.
US6562862B1 (en) 1994-10-20 2003-05-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
EP0895781A3 (en) 1994-10-20 1999-07-07 Eli Lilly And Company Use of benzofurans, benzothiophenes or indoles for the manufacture of a medicament for the treatment of conditions associated with an excess of tachykinins
CA2203878C (en) 1994-11-07 2002-06-25 John M. Peterson Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Also Published As

Publication number Publication date
AU4159297A (en) 1998-03-06
DE69713402D1 (de) 2002-07-18
EP0984778A4 (en) 2000-06-07
EP0984778A1 (en) 2000-03-15
JP2001502296A (ja) 2001-02-20
DE69713402T2 (de) 2002-11-07
CA2268051A1 (en) 1998-02-26
ATE218859T1 (de) 2002-06-15
WO1998007420A1 (en) 1998-02-26
US6849733B1 (en) 2005-02-01
PT984778E (pt) 2002-09-30
DK0984778T3 (da) 2002-09-16
EP0984778B1 (en) 2002-06-12

Similar Documents

Publication Publication Date Title
ES2176776T3 (es) Ligandos del neuropeptido-y.
DK1204654T3 (da) Benzofurylpiperaziner og benzofurylhomopiperaziner: Serotonin agonister
BR9808491A (pt) Compostos calcilìticos
ATE228111T1 (de) M-amidinophenyl-analoga als faktor-xa-inhibitoren
RS49688B (sr) Novi derivat 3-aril-2- hidroksipropionske kiseline (i)
IT1269176B (it) Eterobicicli ad attivita' fungicida
BG103310A (en) Benzonaphthyridins as bronchial therapeutical means
SE0004245D0 (sv) Novel compounds and their use
MY105344A (en) New sulphonyl compounds
PL310940A1 (en) Organic compounds
ATE245642T1 (de) Benzamide mit tetrahydrofuranyloxy-substituenten als inhibitoren der phosphodiesterase 4
TR199903014T2 (xx) 5-HT1F Agonistleri olarak yararl� karboksamitler.
ES2178765T3 (es) Nuevos derivados de 1,7,7-trimetil-biciclo (2.2.1) heptano.
RS50002B (sr) Eletriptan hidrobromid monohidrat
DK1204659T3 (da) Serotonerge benzofuraner
ATE280169T1 (de) Serotonerge benzothiophene
BG103789A (en) Fungicidal compositions
GB2324091A (en) Metalloproteinase inhibitors
FR2693911B1 (fr) Nouvelles utilisations d'un appareillage d'électro-anesthésie.
EA199900534A1 (ru) Имидазопиридазины
IT1271443B (it) Derivati eterobiciclici ad attivita' fungicida
MX9602949A (es) 2-oxa y tia-zolinas artropodicidas.
IT1254199B (it) Tiazolilpirroli ad attivita' fungicida
BG105252A (en) Isoquinolines as urokinase inhibitors
TR199701011A2 (xx) 1-karba-(detia)-sefalosforin t�revleri.